menu search

TVTX / Travere: Turbulent Journey With FILSPARI, Downgrading To Sell

Travere: Turbulent Journey With FILSPARI, Downgrading To Sell
FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the Phase 3 DUPLEX study raises doubts about its IgAN trial and eventual approvability in FSGS. FILSPARI's sales, largely inventory-driven, may not predict actual market potential. We downgrade to sell rating as we are bearish on the PROTECT readout and also believe the upcoming sales data won't be a meaningful enough catalyst to change the trajectory. Read More
Posted: May 29 2023, 03:49
Author Name: Seeking Alpha
Views: 110519

TVTX News  

Travere Therapeutics to Report Third Quarter 2023 Financial Results

By GlobeNewsWire
October 24, 2023

Travere Therapeutics to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial res more_horizontal

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

By GlobeNewsWire
October 13, 2023

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsent more_horizontal

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

By GlobeNewsWire
September 26, 2023

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will pr more_horizontal

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

By Zacks Investment Research
September 22, 2023

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely more_horizontal

Why Shares of Travere Therapeutics Are Slumping Thursday

By The Motley Fool
September 21, 2023

Why Shares of Travere Therapeutics Are Slumping Thursday

Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. more_horizontal

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

By GlobeNewsWire
August 24, 2023

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fro more_horizontal

Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
August 3, 2023

Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth consideri more_horizontal

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 3, 2023

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to more_horizontal


Search within

Pages Search Results: